Study of Epidemiologic Investigation and Mechanism of Brain Network of Otologic and Cognitive Function With Post-COVID-19 (COVID-19)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed cases of COVID-19 that test positive for nucleic acid or antigen
- After infection with COVID-19, the patient has experienced hearing loss, tinnitus, ear tightness, ear pain, vertigo and other ear symptoms, memory loss, depression and so on
Exclusion Criteria:
- Diagnosed cognitive disability
- Patients with confirmed Meniere's disease, auditory neuropathy, and heavy noise exposure
- Those with incomplete basic information or for other reasons are unable to complete questionnaires and other listening and cognitive assessments
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with hearing loss after infection
|
|
Patients with hearing loss before infection
|
|
Healthy control
Healthy subjects who have never been infected with COVID-19 or diagnosed with hearing loss.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The correlation between the peak of COVID-19 transmission and the popularity of related online terms
Time Frame: through study completion, an average of 3 months
|
The correlation between the peak of COVID-19 transmission and the popularity of related online terms
|
through study completion, an average of 3 months
|
|
Symptom incidence
Time Frame: through study completion, an average of 3 months
|
According to the questionnaire survey of 748 patients, the incidence of hearing loss, tinnitus, ear tightness, earache, vertigo or other cognitive and emotional problems after COVID-19 was analyzed.
|
through study completion, an average of 3 months
|
|
Pure tone average
Time Frame: through study completion, an average of 3 months
|
According to the WHO grading standard of hearing loss in 1980, the average pure tone threshold (PTA) of 0.5k, 1k, 2k and 4kHz in better ears was defined as normal hearing, 26-40 dB HL(hearing level) was defined as mild hearing loss, and 41-55 dB HL was defined as moderate hearing loss.
56-70 dB HL was moderate to severe hearing loss, 71-90 dB HL was severe hearing loss, and ≥91 dB HL was extremely severe hearing loss.
|
through study completion, an average of 3 months
|
|
Mini-Mental State Examination score and grade
Time Frame: through study completion, an average of 3 months
|
There are 30 points in the Mini-Mental State Examination (MMSE) scale.
The score of 27-30 is normal, and 21-26 is mild dementia.
10-20 is moderate dementia; On a scale of 0 to 9, dementia is severe
|
through study completion, an average of 3 months
|
|
Montreal Cognitive Assessment score and grade
Time Frame: through study completion, an average of 3 months
|
The total score of the Montreal Cognitive Assessment (MoCA) scale is 30 points, generally ≥26 points normal, 18-26 points mild cognitive impairment, 10-17 points moderate cognitive impairment, and < 10 points severe cognitive impairment.
|
through study completion, an average of 3 months
|
|
Pittsburgh Sleep Quality Interview score and grade
Time Frame: through study completion, an average of 3 months
|
Pittsburgh Sleep Quality Index (PSQI) Scale total scores 21 points.
A score of 0-5 indicates good sleep quality; A score of 6-10 indicates good sleep quality; 11-15 points, indicating average sleep quality; A score of 16 to 21 indicates poor sleep quality
|
through study completion, an average of 3 months
|
|
Hamilton depression score and grade
Time Frame: through study completion, an average of 3 months
|
For the 24th version of Hamilton depression Scale (HAMD), the total score > 35 May indicate severe depression; 21-35, may be mild to moderate depression; 9-20, suspected depression; < 8 indicates normal.
|
through study completion, an average of 3 months
|
|
Resting state of Electroencephalogram data
Time Frame: through study completion, an average of 3 months
|
Electroencephalogram (EEG) data of the study were preprocessed and trends in functional brain network connectivity were analyzed.
|
through study completion, an average of 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurocognitive Disorders
- Otorhinolaryngologic Diseases
- Cognition Disorders
- COVID-19
- Cognitive Dysfunction
- Ear Diseases
Other Study ID Numbers
Other Study ID Numbers
- SYSKY-2023-151-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.